Inhibition of osteoclast differentiation and activation, by blocking of RANKL signaling or RANK expression has been shown to decrease osteolytic prostate cancer growth in bone in experimental in vivo settings [15–17]. The gene discussed is TNFSF11; the disease is prostate cancer.